2025-05-06T12:33:24-05:00 2024-12-31 233018514 DUNLAPSLK PC 1300 HORIZON DRIVE SUITE 106 CHALFONT PA 18914 990 2024-01-01 232740843 ALTERNATIVES RESEARCH AND DEVELOPMENT FO ALTE 2158878076 801 OLD YORK ROAD 218 JENKINTOWN PA 19046 SUE A LEARY PRESIDENT 2158878076 2025-04-23 1 0 JULIA L DAVIS P00163568 2675943755 2025-04-22 2024 2025-03-06 01:10:19Z SUE A LEARY 801 OLD YORK ROAD 218 JENKINTOWN PA 19046 4547866 0 X WWW.ARDF-ONLINE.ORG X 1993 PA ARDF PROMOTES AND DEVELOPS ALTERNATIVE SCIENTIFIC SOLUTIONS TO THE PROBLEM OF ANIMAL TESTING. 8 6 1 10 0 0 77619 1233029 0 0 673249 896388 0 0 750868 2129417 266937 413605 0 0 47461 54703 0 0 3879 320027 366181 634425 834489 116443 1294928 14204946 16848676 16178 44137 14188768 16804539 X THE MISSION OF THE ARDF IS TO FUND AND PROMOTE THE DEVELOPMENT, VALIDATION AND ADOPTION OF NON-ANIMAL METHODS IN BIOMEDICAL RESEARCH, PRODUCT TESTING, AND EDUCATION. 0 0 648559 413605 THE "ANNUAL OPEN" GRANT PROGRAM FUNDS INNOVATIVE ALTERNATIVE METHODS TO REDUCE OR REPLACE ANIMAL USE IN RESEARCH AND TESTING.IN 2024, ARDF FUNDED THE FOLLOWING PROJECTS FOR SCIENTIFIC RESEARCH: 1) NEW HUMAN MODELS FOR THE STUDY OF ATRIAL FIBRILLATION; 2) IN VITRO TRANSPLANTATION MODELING USING INDUCED PLURIPOTENT STEM CELL-DERIVED GRAFTS; 3) MODELING HUMAN BONE MARROW ENGRAFTMENT AND HEMATOPOIESIS IN A MICRO-FLUIDIC PLATFORM; 4) A HUMAN BLADDER MODEL TO DECIPHER HOST-UROPATHOGEN INTERACTIONS FROM TISSUE TO SINGLE-CELLS; 5) COMPUTATIONAL DISCOVERY OF LONG NON-CODING RNAS AS NOVEL RELAPSE RISK BIOMARKERS FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA; 6) A HUMAN PRECISION-CUT LUNG SLICE-BASED PLATFORM FOR FIBROTIC DRUG DISCOVERY; 7) DEVELOPING HUMAN CELL-BASED GLIOBLASTOMA MODELS FREE FROM ANIMAL DERIVATIVES; 8) MODELING JOINT PAIN USING AN ANIMAL-FREE SYSTEM ON A CHIP; 9) DEVELOPING A MODEL TO STUDY LIPID BODIES AND SEX-DEPENDENT IMMUNE RESPONSES IN HUMAN MONOCYTE-DERIVED MACROPHAGES; 10) REGULATORY T CELL SUPPRESSIVE FUNCTIONS IN MIGRAINE.THIS YEAR'S FOCUS ON DEVELOPING MODELS TO AID DEVELOPMENT OF TREATMENTS UNDERSCORES THE TREMENDOUS POTENTIAL OF IN VITRO MODELS FOR BIOMEDICAL RESEARCH. BY SUPPORTING RESEARCH TO DEVELOP ALTERNATIVE, ANIMAL-FREE MODELS, ARDF CONTINUES TO ADVANCE BOTH ANIMAL WELFARE AND HUMAN HEALTH.ARDF ALSO ADDED ITS EXPERTISE TO POLICY DISCUSSIONS OF ADVANCING ALTERNATIVE METHODS. FOR EXAMPLE, IN 2024, ARDF PRESIDENT SUE LEARY SERVED ON THE SCIENTIFIC ADVISORY COMMITTEE ON ALTERNATIVE TOXICOLOGICAL METHODS TO A DEPARTMENT OF THE NATIONAL INSTITUTES OF HEALTH. ARDF AWARDED THE WILLIAM AND ELEANOR CAVE AWARD TO ANNA LOWIT, PHD, FOR HER CAREER ACCOMPLISHMENTS IN IMPLEMENTING ALTERNATIVE APPROACHES IN CHEMICAL AND PESTICIDE TESTING. ARDF SPONSORED SCIENTIFIC MEETINGS, AND EDUCATION AND OUTREACH ON ALTERNATIVE METHODS TO ACCELERATE UNDERSTANDING AND COLLABORATION. 648559 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 X 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 PA MN X X THE ORGANIZATION 2158878076 801 OLD YORK ROAD SUITE 218 JENKINTOWN PA 19046 SUE A LEARY PRESIDENT 12.00 35.00 X X 20000 68260 6530 LUKE KLEIN BOARD MEMBER 0.50 35.00 X 0 92215 13486 NADIA S ADAWI BOARD MEMBER 0.50 0.50 X 0 0 0 ROBERT FINN BOARD MEMBER 0.50 0.50 X 0 0 0 FRANCIS KRAFCHIK DECEASED IN 2024 BOARD MEMBER 0.50 0.50 X 0 0 0 JOSEPH LUDWIG VICE PRESIDENT 0.50 1.00 X X 0 0 0 AARON MCINTYRE TREASURER 0.50 1.00 X X 0 0 0 DENISE COWIE SECRETARY 0.50 1.00 X X 0 0 0 20000 160475 20016 1 0 0 0 MORGAN STANLEY 1585 BROADWAY NEW YORK NY 10036 INVESTMENT SERVICES 142930 1 1233029 1233029 241189 241189 3073648 2418449 655199 655199 655199 2129417 0 0 896388 X 314914 314914 10000 10000 88691 88691 20000 20000 19922 7279 10055 2588 11546 7291 3255 1000 3235 2092 902 241 4930 4930 18725 18725 142930 142930 149817 149651 132 34 9508 9098 394 16 18971 18338 633 18919 18919 600 600 81 61 20 RESEARCH AND INFORMATIO 1614 1582 32 POSTAGE AND SHIPPING 86 43 43 834489 648559 182051 3879 80052 46218 1044307 2260339 18075 18069 3358 3250 12396 11496 1500 900 12634377 14050290 423277 469610 14204946 16848676 7496 3677 8682 40460 16178 44137 X 13229485 14624283 959283 2180256 14188768 16804539 14204946 16848676 X 1294928 1306086 14757 X X 0 1 X 1 0 X 74498 69409 333654 77619 1233029 1788209 74498 69409 333654 77619 1233029 1788209 1788209 141897 154090 140054 185725 241189 862955 8505 8505 2659669 0.67230 0.46110 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 106057 293887 330620 730564 1095846 90 22629 21761 44480 26514 73472 82655 182641 273962 15679 15342 31021 12634377 1975913 560000 14050290 10366590 2667787 400000 12634377 14214680 -3448036 400054 10366590 12674289 1890391 350000 14214680 10737802 2311583 375096 12674289 1.00000 0.00000 0.00000 0 0 12396 11496 900 900 LEASE OBLIGATIONS 40258 PAYABLE TO AFFILIATE 202 40460 X 3307330 1306086 -128173 1177913 2129417 0 2129417 691559 0 691559 142930 142930 834489 PART V, LINE 4: THE ORGANIZATION'S QUASI-ENDOWMENT FUNDS FUND THE VARIOUS ACTIVITIES OF ARDF. THIS INCLUDES FUNDING RESEARCH PROJECTS THAT DEVELOP NON-ANIMAL ALTERNATIVES TO TRADITIONAL ANIMAL EXPERIMENTS AND SPONSORSHIP OF SCIENTIFIC MEETINGS PROMOTING ALTERNATIVES. PART X, LINE 2: MANAGEMENT BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX PROVISIONS TAKEN, AND AS SUCH, THE FOUNDATION DOES NOT HAVE ANY UNCERTIAN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: UNREALIZED GAIN ON BENEFICIAL INTEREST IN PERPETUAL TRUST 14,757. INVESTMENT FEES -142,930. 0 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES GRANT PROGRAM MANAGEMENT 131610 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES RESEARCH GRANTS 88691 0 1 0 0 0 1 220301 0 220301 BRAZIL 13TH WORLD CONGRESS ON ALTERNATIVES SPONSORSHIP 20000 WIRE TRANSFER 0 SWITZERLAND DR. CARLOS FLORES RESEARCH GRANT A HUMAN BLADDER MODEL TO DECIPHER HOST-UROPATHOGEN INTERACTIONS FROM TISSUE TO SINGLE-CELLS 39000 WIRE TRANSFER 0 FRANCE DR. EMILY STUCHFIELD-DENBY RESEARCH GRANT - REGULATORY T CELL SUPPRESSIVE FUNCTIONS IN MIGRAINE 29691 WIRE TRANSFER 0 0 0 0 0 0 0 PART I, LINE 2: PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND THE FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY. 1 UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167352 501(C)(3) 40000 0 DR. TIEN-CHAN HSIEH RESEARCH GRANT COMPUTATIONAL DISCOVERY OF LONG NON-CODING RNAS AS NOVEL RELAPSE RISK BIOMARKERS FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA RUSH UNIVERSITY MEDICAL CENTER 1653 W CONGRESS PARKWAY CHICAGO IL 60612 362174823 501(C)(3) 39996 0 DR. RACHEL MILLER RESEARCH GRANT MODELING JOINT PAIN USING AN ANIMAL-FREE SYSTEM ON A CHIP MICHIGAN STATE UNIVERSITY 426 AUDITORIUM ROAD ROOM 2 EAST LANSING MI 48824 386005984 501(C)(3) 40000 0 DR. AITOR AGUIRRE RESEARCH GRANT NEW HUMAN MODELS FOR THE STUDY OF ATRIAL FIBRILLATION DUKE UNIVERSITY SCHOOL OF MEDICINE 2200 WEST MAIN STREET SUITE 1000 ERWIN SQUARE DURHAM NC 27705 560532129 501(C)(3) 40000 0 DR. WONJAE LEE RESEARCH GRANT DEVELOPING HUMAN CELL-BASED GLIOBLASTOMA MODELS FREE FROM ANIMAL DERIVATIVES UNIVERSITY OF WASHINGTON 433 BROOKLYN AVE NW BOX 359472 SEATTLE WA 98195 916001537 501(C)(3) 40000 0 DR. LAURA CRISA RESEARCH GRANT MODELING HUMAN BONE MARROW ENGRAFTMENT AND HEMATOPOIESIS IN A MICRO-FLUIDIC PLATFORM UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK STREET SUITE 6301 MADISON WI 53715 396006492 501(C)(3) 40000 0 DR. MATTHEW BROWN RESEARCH GRANT IN VITRO TRANSPLANTATION MODELING USING INDUCED PLURIPOTENT STEM CELL-DERIVED GRAFTS BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE OV-540 BOSTON MA 02215 042103881 501(C)(3) 40000 0 DR. RAMASWAMY KRISHNAN RESEARCH GRANT A HUMAN PRECISION-CUT LUNG SLICE-BASED PLATFORM FOR FIBROTIC DRUG DISCOVERY UNIVERSITY OF NORTHERN IOWA 213 EAST BARLETT HALL CEDAR FALLS IA 506140394 426004333 501(C)(3) 17915 0 DR. NILDA RODRIGUEZ RESEARCH GRANT - DEVELOPING A MODEL TO STUDY LIPID BODIES AND SEX-DEPENDENT IMMUNE RESPONSES IN HUMAN MONOCYTE-DERIVED MACROPHAGES AMERICAN SOCIETY FOR CELLULAR AND COMPUTATIONAL TOXICOLOGY 30 WEST WATKINS MILL ROAD SUITE 100 GAITHERSBURG MD 20878 272792207 501(C)(3) 5697 0 SPONSORHIP OF ASCCT MEETING EVENT THE WILLIAM & ELEANOR CAVE AWARD - RECOGNITION FOR EXTRAORDINARY ACHIEVEMENTS ADVANCING ALTERNATIVE METHODS FOR TOXICITY TESTING 1 10000 0 PART I, LINE 2: PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND A FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY. FORM 990, PART V, LINE 24 AND PART IX SALARIES REFLECTED ON THE STATEMENT OF FUNCTIONAL EXPENSES INCLUDE ALLOCATIONS OF SALARIES AS A PORTION OF MANAGEMENT EXPENSES THAT THE ORGANIZATION PAYS TO ITS AFFILATE, THE AMERICAN ANTI-VIVISECTION SOCIETY. NOTE THAT THE ONE EMPLOYEE, SUE LEARY, IS PAID BY A COMMON PAYMASTER. THE ORGANIZATION'S AFFILIATE AMERICAN ANTI-VIVISECTION SOCIETY. THERE IS NO W-3 REPORTED FOR THIS ENTITY; ALL FILING REQUIREMENTS ARE MET THROUGH THE AFFILIATE AS MENTIONED. FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT, TREASURER AND BOARD OF DIRECTORS REVIEW THE FORM 990 BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION FOLLOWS THE POLICIES OF ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS), WITH WHICH IT SHARES ITS BOARD OF DIRECTORS. THE BOARD OF DIRECTORS MONITORS AND ENFORCES COMPLIANCE WITH THE CONFLICT OF INTEREST POLICIES (AS DETERMINED BY AAVS). ANNUAL DISCLOSURE FORMS ARE COLLECTED FROM EACH BOARD MEMBER AND REVIEWED BY THE PRESIDENT WHO ENSURES THAT MEMBERS RECUSE THEMSELVES FROM VOTING ON ANY MATTERS IN WHICH THEY MAY HAVE A DUAL INTEREST. THE BOARD OF DIRECTORS, EXCLUDING THE PRESIDENT, ENSURES THAT THE PRESIDENT RECUSES HERSELF IN CASE OF A POTENTIAL CONFLICT OF INTEREST. THE CONFLICT OF INTEREST POLICY EXPLICITLY DEEMS FAMILY AND BUSINESS RELATIONSHIPS TO HAVE POTENTIAL FOR CONFLICTS AND REQUESTS DETAILED INFORMATION ON ANY SUCH RELATIONSHIPS AS PART OF THE ANNUAL CONFLICT OF INTEREST POLICY PROCESS. FORM 990, PART VI, SECTION B, LINE 15A THE ORGANIZATION'S COMPENSATION POLICIES ARE DICTATED BY ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS) WITH WHOM IT SHARES A BOARD OF DIRECTORS. THE BOARD OF DIRECTORS DETERMINES COMPENSATION OF THE PRESIDENT BY COMPARING WITH COMPENSATION OF EQUIVALENT POSITIONS USING PUBLICLY AVAILABLE DATA. NOTE THE PRESIDENT'S SALARY IS DETERMINED BY AAVS BUT IS REPORTED ON BOTH RETURNS. DECISIONS ARE RECORDED IN BOARD MINUTES AND MATERIALS. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT LABOR: PROGRAM SERVICE EXPENSES 149,473. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 149,473. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 178. MANAGEMENT AND GENERAL EXPENSES 132. FUNDRAISING EXPENSES 34. TOTAL EXPENSES 344. FORM 990, PART XI, LINE 9: UNREALIZED LOSS ON BENEFICIAL INTEREST IN PERPETUAL TRUST 14,757. FORM 990, PART XII, LINE 2C: THERE WAS NO CHANGE IN THE AUDIT OVERSIGHT PROCESS FROM THE PRIOR YEAR. AMERICAN ANTI-VIVISECTION SOCIETY 801 OLD YORK ROAD NOBLE PLAZA SUITE JENKINTOWN PA 19046 230341990 EDUCATE THE PUBLIC ON PROBLEMS OF ANIMAL EXPERIMENTATION PA 501(C)(3) LINE 7 NONE 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 AMERICAN ANTI-VIVISECTION SOCIETY M 86 FMV AMERICAN ANTI-VIVISECTION SOCIETY N 2530 FMV AMERICAN ANTI-VIVISECTION SOCIETY O 54340 FMV AMERICAN ANTI-VIVISECTION SOCIETY P 132533 FMV